SCIMED Sustainability Profile
SCIMED, officially known as SCIMED Life Sciences, is a prominent player in the biotechnology industry, headquartered in the United States. Founded in 2010, the company has established itself as a leader in developing innovative medical devices and diagnostic solutions, primarily serving the healthcare sector across North America and Europe. SCIMED's core offerings include advanced imaging systems and precision instruments that enhance clinical outcomes and streamline workflows. What sets SCIMED apart is its commitment to integrating cutting-edge technology with user-friendly designs, ensuring that healthcare professionals can deliver optimal patient care. With a strong market position, SCIMED has achieved significant milestones, including numerous patents and partnerships with leading healthcare institutions. The company continues to drive advancements in medical technology, solidifying its reputation as a trusted name in life sciences.
DitchCarbon Score
How does SCIMED's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SCIMED's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SCIMED, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The organisation is a current subsidiary of Boston Scientific Scimed, Inc., which means that any emissions data or climate commitments would be inherited from its parent company, Boston Scientific Corporation. As part of its climate commitments, SCIMED aligns with the sustainability initiatives of Boston Scientific Corporation, which includes participation in various climate-related frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for SCIMED have not been disclosed. Given the lack of direct emissions data and specific reduction initiatives, SCIMED's climate strategy appears to be integrated within the broader commitments of its parent company. This context highlights the importance of corporate family relationships in understanding the environmental impact and sustainability efforts of subsidiaries like SCIMED.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is SCIMED's Industry?
How Carbon Intensive is SCIMED's Location?
SCIMED's Scope 3 Categories Breakdown
SCIMED's Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
SCIMED's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SCIMED has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
